Dr. McKay on FDA Approval of Frontline Cabozantinib in RCC

Rana R. McKay, MD
Published: Tuesday, Dec 19, 2017



Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of cabozantinib (Cabometyx) in the frontline setting for patients with renal cell carcinoma (RCC).
SELECTED
LANGUAGE


Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of cabozantinib (Cabometyx) in the frontline setting for patients with renal cell carcinoma (RCC).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x